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Abstract
Antiphospholipid syndrome (APS), also known as Hughes Syndrome, is a
systemic autoimmune disease characterized by thrombosis and/or pregnancy
morbidity in the presence of persistently positive antiphospholipid antibodies. A
patient with APS must meet at least one of two clinical criteria (vascular
thrombosis or complications of pregnancy) and at least one of two laboratory
criteria including the persistent presence of lupus anticoagulant (LA),
anticardiolipin antibodies (aCL), and/or anti-b2 glycoprotein I (anti-b2GPI)
antibodies of IgG or IgM isotype at medium to high titres in patient’s plasma.
However, several other autoantibodies targeting other coagulation cascade
proteins (i.e. prothrombin) or their complex with phospholipids (i.e.
phosphatidylserine/prothrombin complex), or to some domains of β2GPI, have
been proposed to be also relevant to APS. In fact, the value of testing for new
aPL specificities in the identification of APS in thrombosis and/or pregnancy
morbidity patients is currently being investigated.
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Introduction
Antiphospholipid syndrome (APS), also known as Hughes 
Syndrome, is a systemic autoimmune disease characterized by 
thrombosis and/or pregnancy morbidity in the presence of persist-
ently positive antiphospholipid antibodies1. When APS was first 
described, it was in the presence of systemic lupus erythematosus 
(SLE)2; however APS is now accepted to be a primary autoim-
mune syndrome with other accompanying characteristics, such as 
thrombocytopenia, seizure disorder, cognitive dysfunction, livedo 
reticularis, and renal vasculopathy, being frequent in the absence 
of the main clinical manifestations of thrombosis and pregnancy 
complications3.
In 1999 definitive classification criteria for APS were published in 
an international consensus statement4 and subsequently revised in 
20061. A patient with APS must meet at least one of two clinical 
criteria (vascular thrombosis or complications of pregnancy) and at 
least one of two laboratory criteria including the persistent presence 
of lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and/
or anti-β2 glycoprotein I (anti-β2GPI) antibodies of IgG or IgM 
isotype at medium to high titres in patient’s plasma.
While it is widely accepted that the LA is the most important pre-
dictor for thrombosis5–7, several other autoantibodies targeting other 
coagulation cascade proteins (i.e. prothrombin) or their complex 
with phospholipid (i.e. phosphatidylserine/prothrombin complex), 
or to some domains of β2GPI, have been proposed to be relevant 
to APS8. In fact, the value of testing for new aPL specificities in 
the identification of APS in thrombosis and/or pregnancy morbidity 
patients is currently being evaluated, which will be especially use-
ful for those with recurrent negative results in present tests9.
New aPL specificities
Antibodies directed to the domain I of the β2GPI
β2GPI was identified as a primary target of autoantibodies in 
patients with APS10. β2GPI is a single-chain protein containing 
five repeating sequences or domains. Domain V is essential for 
binding to anionic phospholipid membranes, whereas domain I 
sticks out into the extracellular space where interactions with other 
proteins/antibodies can take place11. The development of recom-
binant domain specific β2GPI molecules by Iverson et al. in 199812 
steered us towards a better understanding of the specific role of the 
autoantibodies to each of the five β2GPI domains. Several studies 
have detected antibodies recognizing various domains of β2GPI13. 
However, anti-domain I (anti-DI) antibodies were frequently found 
to be highly associated with clinical symptoms and therefore 
focused upon14,15.
In their 2005 study, de Laat et al. reported that patients testing 
positive for anti-DI had a higher thrombosis risk14. Antibodies 
recognizing epitope G40-R43 on the domain I of β2GPI caused 
LA and strongly correlated with thrombosis14. A larger, multicen-
tre study in 2009 looked at a large cohort of anti-β2GPI positive 
patients, showing that those patients who were IgG anti-DI positive 
had a 3.5 fold increase in the risk of developing vascular throm-
bosis and a 2.4 fold increase in the risk of developing pregnancy 
morbidity when compared to those who tested negative for IgG 
anti-DI16. Using inhibition assays, Banzato et al. demonstrated that 
high-risk patients, those bearing triple aPL positivity for aCL, LA 
and anti-β2GPI, are those with substantially greater titre of circu-
lating anti-DI antibodies. Those with double and single positivity 
showed low titre or absence of anti-DI antibodies17. Conversely, 
when tested on 326 patients with SLE, of whom 164 had a history 
of thrombosis, Akhter et al. failed to find an association between 
anti-DI and these events18.
The domain profile of anti-β2GPI antibodies has also been 
explored in a large cohort of patients. While neither anti-DI nor 
anti-DIV/V antibodies were found to be associated with throm-
botic events or obstetric morbidity, Andreoli et al. suggested 
that utilizing the ratio of anti-DI/anti-DIV/V could be useful 
as a biomarker for APS, identifying “pathogenic” from “non- 
pathogenic” anti-β2GPI15. A recent study in aCL and/or aβ2GPI 
positive patients suggests that the added finding of anti-DI 
positivity makes it three to five times more likely to confirm APS. 
Positivity for IgG or IgA (but not IgM) anti-DI increased the 
strength of association between aCL/aβ2GPI and thrombotic mani-
festations in APS19.
Anti-DI antibodies have also been reported in pediatric popu-
lations. Wahezi et al. reported a prevalence of IgG anti-DI of 
25.1% in children with SLE. However, only seven children had 
thrombosis, failing to ascertain a positive correlation20. In a study 
on 64 APS patients and 57 children born to mothers with systemic 
autoimmune diseases, Andreoli et al. showed a high prevalence of 
anti-DI in APS while there was a low anti-DI frequency reported in 
anti-β2GPI positive healthy children21.
A direct demonstration of the pathogenic effect of anti-DI antibodies 
has been recently shown using a human monoclonal IgG (MBB2), 
the infusion of which brought about fetal losses in pregnant mice 
and blood clots in rat mesenteric microcirculation following prim-
ing with lipopolysaccharide (LPS)22. Interestingly, a variant of this 
antibody, lacking the CH2 domain (MBB2DΔCH2), was effective 
in preventing blood clot formation and fetal loss induced by aPL22. 
A recombinant human domain I has also been shown to inhibit the 
ability of polyclonal human IgG from a patient with APS to cause 
thrombosis or to enhance tissue factor activity in an animal model23. 
Using polyclonal IgG from patients with APS, anti-domain I-rich 
IgG significantly enhanced prothrombotic ability in vivo compared 
with anti-domain I-poor or NHS-IgG, suggesting that the ability of 
human APS-derived IgG to cause thrombosis in mice is concen-
trated in the anti-domain I-rich fraction24.
A novel approach for developing therapy for APS has shown that 
tolerogenic dendritic cells specific for domain-I of the β2GPI 
molecule may have potential in attenuating experimental APS in 
a murine model, via acceleration of the differentiation of CD4+ T 
cells to Treg cells, decreased proinflammatory cytokine production, 
and increased anti-inflammatory cytokine expression (IL-10 and 
TGFβ)25.
Antibodies to prothrombin
Prothrombin (factor II) is an important antigenic target for aPL in 
APS. Prothrombin is a vitamin K-dependent single-chain glyco-
protein of 579 amino acid residues with a molecular weight of 
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72-kDa. It circulates in normal plasma at a concentration of approx-
imately 100 μg/ml26. Antibodies directed to human prothrombin 
(aPT) and the complex of phosphatidylserine/prothrombin (aPS/
PT) are detected by ELISA and have been strongly associated with 
APS27. While the presence of these antibodies have been shown to 
correlate in some cases28, it seems that aPT and aPS/PT belong to 
different populations of autoantibodies9.
A systematic review of the literature including 6000 patients and 
1400 controls has been recently reported27. aPS/PT was shown to 
represent a stronger risk factor for thrombosis, both arterial and/or 
venous, than aPT, with an odds ratio (OR) of 527. Data from our 
group and others suggest that the risk of thrombosis progressively 
increases with the increase in number of positive aPL tests29–32. 
Recently, we showed that testing positive for all three antibodies—
LA, anti-β2GPI and aPS/PT— was the best diagnostic indication of 
APS33. In addition, when compared with double or single positivity, 
this triple combination showed a stronger correlation with clinical 
events (thrombosis and/or pregnancy loss).
The mechanisms underlying the procoagulant properties of anti-
bodies to prothrombin are not known; currently two are being 
postulated: a) indirect; through humoral regulators of coagulation 
(i.e. prothrombin) or b) direct; engaging/activating cell receptors. 
An isolated report suggests that polyclonal antibodies from patients 
with antiprothrombin antibodies might act on a ‘target’ molecule 
expressed at the endothelial cell surface34, although this is as yet 
uncharacterised. Tissue factor production induced by aPS/PT in 
procoagulant cells is reported to occur predominantly via activation 
of the p38 mitogen-activated protein kinase (MAPK) pathway35, 
similar to the mechanisms implicated in anti-β2GPI-induced cell 
activation36. In the mouse, active immunisation with prothrombin 
is associated with increased thrombosis, supporting a role for anti-
bodies to prothrombin in thrombus formation37. In addition, mice 
treated with IS6 (a mouse monoclonal antiprothrombin antibody) 
show thrombi that are larger and persist longer than in mice injected 
with control antibody34.
Pathogenic mechanisms of aPL
Despite our incomplete understanding of APS pathogenesis, the 
major facets have been defined in recent years. Thrombosis, a key 
feature of the disease, can be the result of various mechanisms, 
including endothelial cells, monocytes, platelets, coagulation, and 
complement pathways, as well as blocking of the fibrinolytic and 
anticoagulation pathways. The conventional understanding is that 
aPL antibodies bind to receptors on target cells, causing their acti-
vation and leading to thrombosis in large vessels38. A number of 
processes have been implicated as effectors of a prothrombotic 
state in APS. These include: the generation of tissue factor39,40; 
complement activation41–43; activated platelet-enhanced endothelial 
activation44,45; monocyte protease receptor activation46; and the 
generation of DNA nets by neutrophils44,45.
aPL have been proposed to bind to cellular membranes via various 
different receptors, including annexin A247–50, apolipoprotein 
E receptor 2 (ApoER2)51–53, low-density-lipoprotein receptor 
(LDL-R)54, megalin55, Toll-like receptors 256,57 and 450,58, and the 
very-LDL-R and P-selectin glycoprotein (GP) ligand-1. It has also 
been shown that β2GPI is able to directly bind to the platelet adhe-
sive receptor GPIbα59,60 and the platelet factor4 (PF4)61.
Antibody binding to aPL receptors on target cells activates intra-
cellular mediators like nuclear factor kappa B (NF-κB) and 
p38MAPK62.
aPL have also been shown to activate the phosphatidylinositol 
3-kinase (PI3K)–AKT pathway. Activation of this signaling 
cascade engages the mammalian target of rapamycin (mTOR), a 
kinase modulating cellular growth, proliferation and survival63. 
Polyclonal aPL from APS patients induced a marked increase in 
S6RP and AKT (Ser473) phosphorylation, two of the components 
of the mTOR pathway, mediating intimal hyperplasia and chronic 
vasculopathy often seen in APS63.
aPL and the Coagulation System
aPL have been reported to inhibit the anticoagulant properties of 
activated protein C (APC)64,65, impair fibrinolysis66–69, reduce tissue 
factor pathway inhibitor (TFPI) activity70,71 and β2GPI-thrombin 
interaction72,73, and disrupt the annexin A5 anticoagulant shield74–77. 
The binding of aPL to β2GPI diminishes β2GPI complement 
regulatory function with the consequent impaired clearance of 
apoptotic cells78.
aPL as risk factors for thrombosis: Scoring Systems 
in APS
One of the unexplained matters in APS is why some patients 
develop thrombotic events while others present with morbid-
ity in pregnancy. While a minority of patients may also develop 
a life-threatening “catastrophic” form of APS with multiple organ 
involvement and a high death rate, others never develop any aPL-
related manifestation.
In this context, assessing the patient risk of developing an aPL-
related manifestation is crucially important for physicians. 
Three score systems have been formulated to quantify the risk of 
thrombosis/obstetric events in APS31,79,80.
In 2011, a risk model for APS diagnosis was developed based 
on patient positivity for aPL along with their titre and the results 
obtained for LA investigation31. Probability estimates for diagno-
sis of APS were obtained using logistic regression equations and 
the authors demonstrated that multiple aPL positivity, primarily the 
triple association of LA, aCL and anti-β2GPI, increased the risk of 
APS. LA was shown to be the strongest aPL associated with the 
diagnosis of APS.
In an attempt to quantify the risk based on the aPL profile, Otomo 
et al.79 designed the “antiphospholipid score” or aPL-S. The aPL 
profiles were analyzed using six ELISAs (IgG/IgM aCL, IgG/
IgM anti-β2GPI, and IgG/IgM aPS/PT) and five clotting assays 
for LA. An algorithm generated this score, with each assay being 
assigned different points weighted on the relative risk of having a 
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clinical manifestation of APS. The prevalence of APS manifesta-
tions increased with the increasing aPL-S, suggesting that the 
aPL-S could serve as a marker of the “probability” of APS and a 
valuable tool for predicting thrombosis. An independent validation 
in a separate cohort of 211 consecutive SLE patients confirmed the 
aPL-S correlation with a history of thrombosis or pregnancy loss81.
Our newly developed alternative score for APS diagnosis (Global 
APS score or GAPSS) is based on independent thrombosis and 
pregnancy loss risk factors80. This score accounts for established 
cardiovascular risk factors and the autoimmune antibodies profile 
in addition to the aPL profile (criteria aPL1 and non-criteria aPL82). 
We developed and validated the score system in a SLE cohort. The 
analysis included data on clinical manifestations, conventional 
cardiovascular risk factors, aPL and autoimmune profile (including 
ANA, ENA and anti-dsDNA, among others). Weighted points 
proportional to the β-regression-coefficient values were assigned 
to each independent risk factor identified by multivariate analysis. 
Validation was performed in a second cohort of patients showing 
statistically significant higher values of GAPSS in those with a 
clinical history of thrombosis and/or pregnancy loss when 
compared to those without events.
When applied in a prospectively followed-up cohort of SLE 
patients, an increase in the GAPSS during this follow up was 
found to be associated with a 12-fold increase in the risk of vas-
cular events. In detail, an increase of more than 3 GAPSS points 
seemed to have the best risk accuracy for vascular events with a 
hazard ratio of 4883. 
This score was also applied to a cohort of primary APS, higher 
values of GAPSS were seen in APS patients who experienced 
thrombosis when compared to those with previous pregnancy 
loss alone. In addition, GAPSS was able to discriminate patients 
who experienced recurrent thrombotic events from those without 
recurrences84.
This score was independently validated by two groups. Zuily et al.85 
evaluated the validity of the GAPPS to predict thrombosis in 
a prospective multicentre cohort study. GAPSS values were 
significantly higher in patients who experienced a thrombotic event 
when compared to those without with a reported GAPSS above 
16 as a significant predictor of thrombosis in this population. Oku 
et al.86 confirmed that GAPSS can be successfully used to 
quantify risk in an independent cohort of patients with autoim-
mune diseases. GAPSS correlated with a history of APS symptoms, 
particularly with thrombosis, implying it can be used as an 
appropriate quantitative marker for APS.
Classification vs. diagnostic criteria
As stated above, in 1999, definitive classification criteria for APS 
were published in an international consensus statement4 and a 
subsequent revision was made in 20061. A patient with APS must 
meet at least one of two clinical criteria (vascular thrombosis or 
complications of pregnancy) and at least one of two laboratory 
criteria including the persistent presence of lupus anticoagulant 
(LA), anticardiolipin antibodies (aCL) and/or anti-β2GPI anti-
bodies of IgG or IgM isotype at medium to high titres in patient’s 
plasma.
These classification criteria are aimed at identifying well defined, 
relatively homogeneous group of patients, all sharing key features 
of the condition, as they do not reflect the different features of 
the disease, as diagnostic criteria should87. To date, there are no 
diagnostic criteria available for APS and, therefore, even with a 
lack of ‘essential’ or ‘key’ features, clinicians should be encour-
aged to consider the diagnosis in the presence of ‘minor’ features, 
providing other causes have been ruled out.
aPL carriers
Overall data from available studies suggest that asymptomatic 
aPL carriers bear a 0–2.8% annual risk of developing a thrombotic 
event88. While the presence of aPL is necessary but not sufficient to 
provoke a thrombotic event, the “second hit” hypothesis suggests 
that an additional trigger is needed to initiate a vascular event in 
aPL carriers.
An early study from 199889 evaluated the prevalence of thrombo-
sis in aCL positive patients with SLE. The authors reported that 
52% of aCL carriers developed a thrombotic event during the 
10-year follow up, opening the question on the importance of these 
antibodies as risk factors for thrombosis. From then, few other 
studies have estimated the incidence of thrombosis in asympto-
matic carriers with aPL. A total of 178 asymptomatic aPL carri-
ers without underlying autoimmune diseases underwent a 3-year 
prospective observational cohort study and no thrombotic events 
were reported during follow up90. The APLASA study, a ran-
domized, double-blind, placebo-controlled trial investigating 
the efficacy of low-dose aspirin (LDA) as primary prevention of 
thrombotic events showed a low incidence of thrombosis in aPL 
carriers, events occurring in all but one of the cases, in the presence 
of concomitant thrombosis risk factors and/or systemic autoim-
mune disease at the time of thrombosis91. A prospective study 
identified hypertension and LA as independent risk factors for a 
first thrombotic event in asymptomatic aPL carriers92.
A recent study evaluating the efficacy and safety of LDA vs. LDA 
plus low-intensity warfarin in the primary thrombosis prevention 
of aPL-positive patients with SLE and/or obstetric morbid-
ity reported an incidence of 1.8 events/100 person-years in the 
randomized group93. Interestingly, this incidence was increased to 
4.9 events/100 person-years in the observational arm with hyper-
tension being the most frequent additional risk factor.
Evidence shows that patients with more than one positive test, and 
particularly those with all three positive aPL tests (referred to as 
triple positive), are those with a strong association with clinical 
events29,30. Therefore, aPL carriers should be risk-stratified 
according to the aPL status, the presence of other cardiovascu-
lar risk factors that should be closely monitored and controlled 
whenever possible, and the concomitance of other systemic 
autoimmune diseases.
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Conclusions
Studies are underway to establish the value of testing for new aPL 
specificities in the identification of APS in patients with thrombosis 
and/or pregnancy morbidity, particularly in those for whom repeated 
testing produces negative results with currently available methods. 
While their clinical importance and mechanisms of action are far 
from being fully explored, available data suggest that the presence 
of these other aPL, particularly anti-DI and aPS/PT antibodies, are 
useful for risk stratification.
Ongoing research focuses on cell receptors and intracellular 
signaling pathways involved in the cell activation mediated by 
aPL. The clarification of these mechanisms is crucial to a better 
understanding of pathogenesis of APS. Although some contro-
versial data still exist in regards to new specificities, most of the 
available reports support the association between aPS/PT, and to 
a lesser extent anti-DI, and the clinical manifestations of APS. 
Additional studies to conclusively define the relevance and prog-
nosis impact of testing for these antibodies in the daily routine 
clinical practice are still required.
When assessing risk, the use of GAPSS may provide valuable 
information regarding thrombosis or pregnancy loss risk, switching 
from the concept of aPL as simply diagnostic antibodies to aPL 
as relevant risk factors for clinical events.
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